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Background: Chronic hepatitis C (CHC) causes liver cirrhosis in 5%–20% of patients, lead-
ing to increased morbidity and mortality. This study aimed to estimate liver-related morbidity 
and mortality among patients with CHC and cirrhosis in Denmark with and without antiviral 
treatment and sustained virologic response (SVR). Furthermore we aimed to estimate the rate of 
hepatocellular carcinoma (HCC) and decompensation associated with certain prognostic factors.
Materials and methods: Patients with CHC and cirrhosis registered in the Danish Database 
for Hepatitis B and C were eligible. Cirrhosis was based on liver biopsy, transient elastography, 
and clinical cirrhosis. Data were extracted from nationwide registries. The study period was 
from 2002 until 2013.
Results: Of 1,038 patients included, 716 (69%) were male and the median age was 52 years. 
Median follow-up was 3.8 years, 360 patients died, and 233 of 519 treated patients achieved SVR. 
Alcohol overuse and hepatitis C virus genotype 3 were associated with an increased incidence 
rate (IR) of HCC, whereas diabetes and alcohol overuse were associated with increased IRs of 
decompensation. Achieving SVR reduced all-cause mortality (adjusted mortality rate ratio 0.68 
[95% CI 0.43–1.09]) and liver-related mortality (mortality rate ratio 0.6 [95% CI 0.36–1]), as 
well as liver-related morbidity with adjusted IR ratios of 0.37 (95% CI 0.22–0.62) for HCC and 
0.31 (95% CI 0.17–0.57) for decompensation. The IRs of HCC and decompensation remained 
elevated in patients with alcohol overuse after SVR.
Conclusion: Alcohol overuse, hepatitis C genotype 3, and diabetes were associated with 
liver-related morbidity in patients with CHC and cirrhosis. SVR markedly reduced liver-related 
morbidity and mortality; however, special attention to patients with alcohol overuse should 
continue after SVR.
Keywords: chronic hepatitis C, cirrhosis, liver-related morbidity, cohort study, sustained 
virologic response
Plain-language summary
Chronic infection with hepatitis C virus (HCV) can cause liver cirrhosis in 5%–20% of patients. 
With cirrhosis, the risk of liver cancer and complications increases dramatically; however, 
successful antiviral treatment of chronic hepatitis C (CHC) reduces this risk. Little is known 
about the risk of liver cancer, complications, and death in patients with CHC and cirrhosis in 
Denmark. Therefore, this study aimed to estimate the incidence of liver cancer, liver complica-
tions, and liver-related death and how these were affected by successful antiviral treatment in 
patients with CHC and cirrhosis in Denmark. We performed an observational cohort study of 
nationwide data, and found that among patients with CHC and cirrhosis, HCV genotype 3 and 
alcohol overuse were associated with development of liver cancer, whereas diabetes mellitus 
was associated with development of liver complications. Curing CHC significantly reduced the 
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rate of liver cancer and complications, as well as the rate of death. 
There is an urgent need to cure patients with CHC and cirrhosis, 
especially those with HCV genotype 3, and special attention needs 
to be given to patients with diabetes mellitus or alcohol overuse.
Introduction
Chronic infection with hepatitis C virus (HCV) is a disease of 
global importance with a large burden of morbidity and mor-
tality.1–6 For 5%–20% of chronic hepatitis C (CHC) patients, 
the disease will progress to liver cirrhosis7 associated with 
complications, such as liver decompensation, hepatocellular 
carcinoma (HCC), and increased mortality.8 The commonest 
causes of death among patients with CHC and cirrhosis are 
liver-related, particularly HCC.8,9 Several prognostic factors, 
such as diabetes mellitus, male sex, alcohol abuse, and HCV 
genotype 3, are thought to be associated with the development 
of HCC, decompensation, and mortality.10–14
Absence of HCV RNA 24 weeks after end of treatment 
(EOT
24
) is considered a cure for CHC, and is termed sustained 
virologic response (SVR).15 Patients with CHC and cirrhosis 
have previously been difficult to cure; however, achieving a 
cure for CHC has been shown to be associated with decreased 
morbidity and mortality.10,12 With the introduction of new, 
very effective antiviral drugs that cure CHC in nearly all 
treated patients,16 large cohorts of patients with CHC and 
cirrhosis who fail treatment in comparison with patients with 
SVR will be difficult to assemble.
Moreover, our knowledge of liver-related morbidity and 
mortality and how SVR affects these among patients with 
CHC and cirrhosis on a nationwide scale is limited. Most 
previous studies of HCC, decompensation, and liver-related 
mortality in CHC patients with cirrhosis have been single- or 
few-center studies, and included fairly selected cohorts from 
tertiary centers.5,8,10,12,13
The aims of this nationwide cohort study were to estimate 
liver-related morbidity and mortality among patients with 
CHC and cirrhosis in Denmark with and without antiviral 
treatment, and to estimate liver-related morbidity and mor-
tality associated with SVR in a relatively large cohort of 
treated CHC patients with cirrhosis. Furthermore, we aimed 
to estimate the rates of HCC and decompensation associated 
with certain prognostic factors.
Materials and methods
This observational cohort study used prospectively collected 
data. The Danish health-care system is publicly funded and 
provides health-care services free of charge to the individual. 
Patients were identified in the Danish Database for  Hepatitis B 
and C (DANHEP). DANHEP is a nationwide database with 
ongoing enrolment established January 1, 2002.17 It contains 
demographic, clinical, liver-biopsy, laboratory, and treatment 
data, and transient-elastography measurements on patients 
seen with CHC and/or CHB in any of the specialized outpa-
tient clinics responsible for CHC patients in Denmark after 
January 1, 2002. Cross-linkage between nationwide registries 
is possible due to the unique 10-digit personal identification 
number18 given to all residents in Denmark and registered in 
the Danish civil registration system, along with date of birth, 
sex, vital and migration status, and address. All hospital-
admission dates and diagnoses are registered in the Danish 
national patient registry (NPR),19 histopathologic diagnoses 
are registered in the national Danish pathology database (Pato-
bank),20 causes of death are registered in the Danish registry 
of causes of death,21 and cancer diagnoses are registered in the 
Danish cancer registry.22 Further information about the Danish 
registry of causes of death is provided in the Supplementary 
material, and the remaining registries are described in more 
detail elsewhere.23
Patient cohort
Eligible patients were registered in DANHEP and fulfilled 
the following criteria: a positive HCV RNA test, cirrhosis 
and enrolment in DANHEP before December 31, 2013, ≥18 
years of age, and a valid personal identification number and 
address in Denmark. All ICD and systematized nomenclature 
of medicine (SNOMED)24 codes used in the definitions of 
inclusion and exclusion criteria, outcomes, and covariates 
are provided in the Supplementary material. To avoid reverse 
causation and inclusion of prevalent cases of decompensation 
and HCC, the first 6 months of observation were excluded. 
Baseline was thus defined as 6 months (183 days) after the 
first date of a diagnosis of cirrhosis and enrolment in DAN-
HEP, whichever occurred last, and could not precede Janu-
ary 1, 2002. Cirrhosis was defined as: liver biopsy (Metavir 
fibrosis score of F4),25 transient elastography (FibroScan; 
Echosens, Paris, France) median elasticity ≥17 kPa26,27 (10 or 
more valid measurements and an interquartile range ≤30% of 
median elasticity),28 or clinical cirrhosis (cirrhosis registered 
in NPR, ascites, hepatic encephalopathy, esophageal varices, 
esophageal variceal hemorrhage, spontaneous bacterial peri-
tonitis). Patients were excluded if they had CHB, HIV infec-
tion, autoimmune hepatitis, or hemochromatosis at baseline.
Definition of outcomes and covariates
The two primary outcomes in the separate analyses of liver-
related morbidity were HCC and decompensation. We defined 
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HCC as a diagnosis registered in Patobank, the Danish regis-
try of causes of death, the Danish cancer registry, or the NPR. 
Decompensated liver cirrhosis was defined as a diagnosis 
registered in the NPR, the Danish registry of causes of death, 
and/or DANHEP of ascites, esophageal variceal hemorrhage, 
hepatic encephalopathy, or spontaneous bacterial peritonitis.
In mortality analyses, the primary outcome was liver-
related and all-cause mortality. All-cause mortality was 
defined as death due to any cause with a date of death reg-
istered in the Danish civil registration system, which was 
updated throughout the study period. Liver-related mortality 
was based on the underlying cause of death registered on 
the death certificate and divided into liver-related and liver-
unrelated. Because the Danish registry of causes of death 
was only updated through December 2012 at the time of data 
extraction, analyses of liver-related mortality were limited to 
before December 31, 2012.
Antiviral treatment was registered in DANHEP and 
defined as reception of at least one dose of antiviral therapy. 
Based on information registered in DANHEP, successful 
treatment was defined as the absence of HCV RNA (SVR) at 
EOT
24
. Only patients who were alive and had negative HCV 
RNA samples at ≥EOT
24
 were categorized as having SVR. 
Non-SVR was defined as a treatment with known treatment 
response that did not result in SVR. Reinfection after SVR 
was defined as at least one positive HCV RNA after a period 
with undetectable HCV RNA after the EOT
24
 date.
Comorbidity was assessed by a time-updated, cumulative 
Charlson comorbidity index (CCI)29 score calculated based on 
ICD codes assigned to hospital contacts registered in the NPR 
(ICD codes modified by Quan et al30 are provided in the Supple-
mentary material). Originally, the CCI score was developed to 
predict short-term, in-hospital mortality, but has subsequently 
been shown to predict long-term mortality.31 Liver disease, 
HCC, and HIV diagnoses were excluded from the CCI score. 
Orthotopic liver transplantation (LTx) was defined as an LTx 
procedure registered in the NPR. Diabetes mellitus was based 
on ICD codes registered in the NPR. Intravenous drug use (IDU; 
ever) was defined as having an IDU-related diagnosis registered 
in the NPR prior to the end of follow-up, self-reported IDU, 
or IDU as route of HCV transmission registered in DANHEP. 
Alcohol overuse was defined as any of the following prior to the 
end of follow-up: alcohol abuse-related diagnosis in NPR, a liver 
biopsy with a histopathologic diagnosis of alcoholic hepatitis or 
alcoholic cirrhosis, or self-reported daily alcohol consumption of 
>36 g alcohol for men and >24 g alcohol for women32 registered 
in DANHEP. Psychiatric disease was defined as a diagnosis of 
psychiatric disease registered in the NPR.
Statistical analysis
Patient characteristics were compared between patient groups 
with Mann–Whitney U test, c2 test, or c2 test with Monte 
Carlo simulations using 10,000 samples. All rates and rate 
ratios were calculated using Poisson regression, where time at 
risk and number of events in different strata were calculated 
using the stratify macro.33
Patients were followed from baseline until the primary 
outcome, exit for other reasons, or end of the study period, 
whichever occurred first. The study ended on December 31, 
2013 except for liver-related mortality, where the last day of 
observation was December 31, 2012. When estimating rates 
in addition to reaching the end of the study period, infection 
with HIV, CHB, autoimmune hepatitis, or hemochromatosis 
led to censoring. Patients with prevalent cases of the primary 
outcome or LTx at baseline were excluded from morbidity 
analyses. A diagnosis of HCC before decompensation when 
decompensation was the primary outcome did not lead to the 
end of follow-up and vice versa. Cumulative-incidence func-
tions of liver-related morbidity in all patients were calculated 
with death, coinfection with HIV or HBV, autoimmune hepa-
titis, hemochromatosis, and LTx as competing risks. Inci-
dence rate ratios (IRRs) of HCC and decompensation were 
calculated to estimate the rates associated with predefined 
prognostic factors (sex, diabetes, alcohol overuse, and HCV 
genotype). In all Poisson regression analyses, CCI score (0, 
1, 2, 3, 4, 5, ≥6), LTx, diabetes, psychiatric disease, HCC, 
and decompensation were introduced as time-dependent cat-
egorical covariates, whereas sex, alcohol overuse, IDU, and 
genotype (1, 2, 3, 4–6, multiple genotypes) were introduced 
as baseline categorical covariates. Age (<40, 40–44,45–49, 
50–54, 55–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85–89, 
and ≥90 years) was used as a continuous, time-dependent 
covariate after testing for log linearity or as a categorical 
variable. In cases of insufficient events, appropriate covariate 
strata were combined to ensure events in all strata.
In estimates of rates of HCC, decompensation and mor-
tality when comparing patients with SVR vs non-SVR time 
at risk were calculated from the first EOT
24
 date with known 
treatment response or baseline, whichever occurred last, until 
the primary outcome or end of follow-up. In addition to the 
reasons mentioned previously, patients were censored at 
reinfection. SVR was introduced as a time-dependent covari-
ate, and the clock-reset approach was applied. Cumulative-
incidence functions in SVR, non-SVR, and untreated patients 
treated death, LTx, SVR, treatment, coinfection with HIV or 
HBV, and other liver diseases as competing events. Untreated 
patients were followed from baseline until initiation of event, 
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treatment, or end of follow-up. All statistical tests were two-
sided with a=0.05. Data handling and statistical analyses were 
performed using SAS 9.4 (SAS Institute, Cary, NC, USA), 
except for cumulative-incidence functions and figures, where 
R (version 3.2.2)34 was used.
Ethics
This study was approved by the Danish Data Protection 
Agency (2013-41-2323) in accordance with Danish law.
Results
Data were extracted from nationwide registries on 5,779 
patients with positive HCV RNA. Of these, 1,306 patients 
had cirrhosis, and after the exclusion of 268 patients, 1,038 
patients were eventually included (inclusion and exclusion of 
patients can be seen in Figure S1). One patient (0.1%) was 
lost to follow-up with unknown address and vital status in the 
Danish civil registration system. Baseline characteristics of all 
patients, untreated and treated, are shown in Table 1. Before 
the end of follow-up, 537 (52%) patients had initiated antiviral 
treatment, of whom 519 patients reached an EOT
24
 date at 
least once. The majority of treatment courses with a known 
treatment outcome consisted of a backbone of IFN (with or 
without Ribavirin).15 Only 45 (7%) patients were treated with 
polyethylene glycolated IFN combined with Ribavirin and a 
direct-acting antiviral (DAA) drug. Two patients were treated 
with Ribavirin monotherapy and failed to achieve SVR. Over-
all, 233 patients achieved SVR (45%), 276 patients achieved 
non-SVR (53%) at least once, and 10 patients had unknown 
treatment response (2%). A total of 27 patients achieved SVR
24
 
after initially failing therapy. Three patients were reinfected 
and did not achieve a second SVR
24
. Characteristics of patients 
at their first EOT
24
 are listed in Table S1.
Patients were followed for a median of 3.8 (range 0.01–
12) and 4,909 years total. After the exclusion of patients with 
prevalent cases of HCC and/or LTx at baseline, among 989 
patients at risk of HCC, 115 patients were diagnosed with 
HCC during follow-up. Similarly among 811 patients at 
risk of decompensation, 153 decompensated during follow-
up. Of 1,038 patients included, 360 eventually died during 
follow-up. Of 299 deaths prior to December 31, 2012, 186 
(62%) died of liver-related causes. The cumulative-incidence 
functions of liver-related morbidity are shown in Figure 1. 
Liver-related morbidity IRs and mortality rates (MRs) for all 
patients and for SVR, non-SVR, and untreated patients are 
shown in Table 2. Adjusted liver-related morbidity IRRs are 
shown in Table 3 for all patients. In adjusted analyses, alcohol 
overuse was associated with increased rates of both HCC 
and decompensation among patients at risk, and compared 
to patients with genotype 1 or 2, genotype 3 was associated 
with an increased rate of HCC. In contrast, male sex and 
diabetes were not significantly associated with HCC. Geno-
type was not associated with decompensation, but diabetes 
was associated with an IRR of 1.65 for decompensation after 
adjusting for confounding.
Median and total follow-up years were 4.8 (range 
0.04–12) and 1,197 after SVR and 3.8 (range 0.04–12) and 
1,444 after non-SVR. Cumulative-incidence functions of 
liver-related morbidity for SVR, non-SVR, and untreated 
patients are shown in Figures 2 and 3. Of the 226 patients 
who achieved SVR and were at risk of HCC, 10 developed 
HCC maximum 6.1 years after SVR
24
. In contrast, of 289 
patients at risk after non-SVR, 47 were diagnosed with HCC. 
After non-SVR, 56 of 266 patients at risk decompensated, 
whereas only 11 of 211 patients decompensated after SVR. 
One patient with SVR and 11 with non-SVR received LTx. 
Adjusted liver-related morbidity IRRs and MRRs for SVR 
vs non-SVR and untreated patients are presented in Table 4. 
Cumulative incidences for 1-, 5-, and 10-year liver-related 
morbidity with death and LTx as competing risks are pre-
sented in Table S2. Achieving SVR was associated with 
a reduced rate of HCC, even after adjusting for sex, age, 
alcohol overuse, genotype, and diabetes. The rate of decom-
pensation was also reduced substantially in the presence of 
SVR, and of the 11 patients who decompensated after SVR, 
seven had a history of alcohol overuse. Adjusted all-cause 
and liver-related MRs were reduced by 34% and 40% with 
SVR, respectively, when taking confounding into account.
Discussion
This nationwide cohort study based on prospectively col-
lected data adds to our knowledge of liver-related morbidity 
and mortality among CHC patients with cirrhosis in a real-
life cohort. We found major differences between untreated 
and treated patients with regard to baseline characteristics 
associated with mortality. A history of alcohol overuse and 
genotype 3 were associated with increased rates of HCC, 
whereas diabetes increased the rate of decompensation, as 
did alcohol overuse. Achieving SVR was associated with 
markedly reduced rates of liver-related morbidity and mortal-
ity after adjustment for confounding. However, a history of 
alcohol overuse was associated with diagnoses of HCC and 
decompensation after SVR.
Patients who did not initiate treatment differed from 
treated patients with respect to several baseline character-
istics, such as comorbidity, decompensated cirrhosis, HCC, 
and a history of alcohol overuse or IDU. These differences 
were reflected in the high all-cause mortality among untreated 
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patients, even compared to patients with non-SVR
24
. These 
differences are probably primarily a result of the selection 
of healthier patients for antiviral treatment, in part due to 
contraindications to polyethylene glycol–IFN-based therapy15 
and other possible factors, such as continuous links to care.
We found IRs of HCC ranging from 0.85 after SVR 
to 3.53 after non-SVR per 100 person-years (PYs). Some 
studies have reported an increased rate of HCC associated 
with HCV genotype 3 independently of alcohol overuse, 
obesity, and diabetes.12,35 The confirmed increased rate of 
HCC associated with genotype 3 observed in our adjusted 
analyses did not take SVR into account. However, given the 
fact that both genotypes 2 and 3 were associated with higher 
chances of SVR36 in the era of IFN and Ribavirin compared 
with genotype 1, we find it unlikely that differences in 
SVR rates among patients with different genotypes should 
explain the observed increased rate of HCC associated with 
genotype 3. We found no statistically significant association 
Table 1 Baseline characteristics of CHC patients with cirrhosis, and subgroups of untreated patients and patients who initiated 
treatment before the end of follow-up
Baseline characteristics All patients Untreated Treated P-valuea
n 1,038 501 537
Age (median years, range) 51.9 (26–86) 52.2 (26–86) 51.7 (28–80) P=0.11
Male, n (%) 716 (69) 358 (71.5) 358 (66.7) P=0.1
CCI, median (range)b
0, n (%)
1–2, n (%)
3–5, n (%)
≥6, n (%)
0 (0–10)
632 (60.9)
321 (30.9)
76 (7.3)
9 (0.9)
0 (0–10)
278 (55.5)
164 (32.7)
52 (10.4)
7 (1.4)
0 (0–6)
354 (65.9)
157 (29.2)
24 (4.5)
2 (0.4)
P<0.0001
Psychiatric disease, n (%) 207 (19.9) 123 (24.6) 84 (15.6) P=0.0003
Diabetes mellitus, n (%) 127 (12.2) 71 (14.2) 56 (10.4) P=0.07
Continent of birth, n (%)
Europec
Africa
Asia
Other
Unknown
861 (83)
41 (4)
105 (10.1)
14 (1.4)
17 (1.6)
434 (86.6)
18 (3.6)
32 (6.4)
8 (1.6)
9 (1.8)
427 (79.5)
23 (4.3)
73 (13.6)
6 (1.1)
8 (1.5)
P=0.003
Transmission, n (%)
IDU
Tattoo/piercing
Vertical
Sexual transmission
Blood/blood product
Needle injury
Multiple
Other reason
Unknown
559 (53.9)
31 (3)
6 (0.6)
13 (1.3)
70 (6.7)
12 (1.2)
8 (0.8)
11 (1.1)
328 (31.6)
303 (60.5)
12 (2.4)
4 (0.8)
6 (1.2)
32 (6.4)
10 (2)
3 (0.6)
3 (0.6)
128 (25.6)
256 (47.7)
19 (3.5)
2 (0.4)
7 (1.3)
38 (7.1)
2 (0.4)
5 (0.9)
8 (1.5)
200 (37.2)
P=0.07
Diagnostic method, n (%)
Liver biopsy
Clinical cirrhosis
Transient elastography
491 (47.3)
384 (37)
163 (15.7)
132 (26.4)
279 (55.7)
90 (18)
359 (66.9)
105 (19.6)
73 (13.6)
P<0.0001
Decompensation, n (%) 224 (21.6) 174 (37.7) 50 (9.3) P<0.0001
HCC, n (%) 42 (4) 28 (5.6) 14 (2.6) P=0.01
HCV genotype 1,d n (%)
HCV genotype 2
HCV genotype 3
HCV genotype 4–6
Unknown genotype
443 (42.7)
63 (6.1)
378 (36.4)
28 (2.7)
126 (12.1)
210 (42)
32 (6.4)
159 (31.7)
12 (2.4)
88 (17.6)
233 (43.4)
31 (5.6)
219 (40.8)
16 (3)
38 (7.1)
P=0.36
ALT, IU/L, median, IQR 83 (48–136) 69 (41–116) 95 (57–152) P<0.0001
Alcohol overuse,e n (%) 591 (56.9) 353 (70.5) 238 (44.3) P<0.0001
IDU,e n (%) 595 (57.3) 323 (64.5) 272 (50.7) P<0.0001
Notes: aPatients who initiated treatment prior to end of follow-up vs untreated patients; ball patients with no known CCI score at baseline were set to have a CCI score 
of 0; cGreenland is part of Denmark; dthree patients had genotypes 1 and 2, nine patients had genotypes 1 and 3, and one patient had genotype 1 and 4; enumber overall and 
percentage of patients with IDU/alcohol overuse before end of follow-up.
Abbreviations: CHC, chronic hepatitis C; CCI, Charlson comorbidity index; HCC, hepatocellular carcinoma; IDU, intravenous drug use HCV, hepatitis C virus; IQR, 
interquartile range.
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between sex or  diabetes and HCC, as has been described 
elsewhere,10,11,13,37,38 whereas diabetes did increase the rate 
of decompensation. Previously, it has been suggested that 
diabetes and genotype 3 are associated with fibrosis pro-
gression39–41 and complications in cirrhotic patients.14 The 
complex carcinogenic biological mechanisms involved in the 
development of HCC in the presence of diabetes and HCV 
genotype 3 are not fully understood. However, steatosis is 
thought to play a key role,42 and diabetes and HCV show signs 
of a synergistic effect in the formation of HCC.13,43 Apart 
from being associated with obesity and diabetes, steatosis 
is also generally accepted to be associated with HCV geno-
type 3,44 which may partly explain the increased risk of HCC. 
Nonetheless, the absence of information on steatosis and 
steatohepatitis in this study precludes any further conclusions 
on this matter. Alcohol overuse is a well-known risk factor,38 
and was also strongly associated with HCC in this study. We 
did not observe an association between male sex and HCC, 
as demonstrated elsewhere,8,10,12,13,45 and we have no good 
explanation for this (crude rate male vs female 1.18 [95% CI 
0.83–1.68] vs adjusted rate 1.21 [95% CI 0.86–1.69] per 100 
PYs). While it was unclear which covariates were included 
Figure 1 Cumulative incidence functions of liver-related morbidity among patients with chronic hepatitis C and cirrhosis, with death and liver transplantation as competing 
risks.
Abbreviation: HCC, hepatocellular carcinoma.
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Table 2 Liver-related morbidity and mortality incidence rates for patients with chronic hepatitis C and for patients with SVR, non-SVR 
and for untreated patients
Morbidity and mortality 
rates
All patients (95% CI) SVR (95% CI) Non-SVR (95% CI) Untreated (95% CI)
All-cause MR 7.33/100 PYs (6.41–8.39) 2.17/100 PYs (1.4–3.38) 6.64/100 PYs (5.28–8.36) 12.12/100 PYs (10.29–14.35)
Liver-related MR 4.38/100 PYs (3.36–5.7) 1/100 PYs (0.58–1.74) 3.87/100 PYs (3.01–4.96) 7.49/100 PYs (5.79–9.69)
HCC IR 2.49/100 PYs (2.12–2.94) 0.85/100 PYs (0.52–1.41) 3.53/100 PYs (2.80–4.45) 2.79/100 PYs (2.17–3.6)
HCC IR with alcohol overuse 3.25/100 PYs (2.65–3.98) 1.36/100 PYs (0.67–2.77) 4.73/100 PYs (3.54–6.32) 2.99/100 PYs (2.21–4.03)
HCC IR without alcohol overuse 1.76/100 PYs (1.34–2.31) 0.62/100 PYs (0.35–1.11) 2.51/100 PYs (1.74–3.63) 2.41/100 PYs (1.51–3.84)
Decompensation IR 3.9/100 PYs (3.32–4.59) 1/100 PYs (0.6–1.65) 4.53/100 PYs (3.63–5.66) 6.08/100 PYs (4.86–7.61)
Abbreviations: SVR, sustained virologic response (24 weeks after end of treatment); MR, mortality rate; PYs, person-years; HCC, hepatocellular carcinoma; IR, incidence 
rate.
Table 3 Adjusted liver-related morbidity IRRs among all patients 
with chronic hepatitis C and cirrhosis
Adjusted morbidity rate ratios IRR (95% CI)
HCC IRR,a male vs female 1.21 (0.86–1.69)
HCC IRR,a diabetes 1.29 (0.89–1.88)
HCC IRR,a alcohol overuse 1.78 (1.29–2.46)
HCC IRR,a genotypeb 2 vs 1 0.61 (0.28–1.34)
HCC IRR,a genotypeb 3 vs 1 1.61 (1.16–2.22)
HCC IRR,a genotypeb 3 vs 2 2.65 (1.20–5.82)
Decompensation IRR,a male vs female 1.29 (0.86–1.93)
Decompensation IRR,a diabetes 1.65 (1.09–2.48)
Decompensation IRR,a alcohol overuse 2.16 (1.51–3.15)
Decompensation IRR,a genotypec 2 vs 1 0.96 (0.48–1.94)
Decompensation IRR,a genotypec 3 vs 1 0.91 (0.63–1.33)
Decompensation IRR,a genotypec 3 vs 2 0.95 (0.46–1.95)
Notes: aAdjusted for age, sex, genotype (1, 2, 3, 4–6, multiple), alcohol overuse, 
and diabetes as appropriate; btype 3 test, P=0.0074 for genotype, df=4; ctype 3 test, 
P=0.94, df=4.
Abbreviations: IRR, incidence rate ratio; HCC, hepatocellular carcinoma.
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in the final multivariate Cox regression models performed 
in previously published studies,8,10,12,13,45 we find it unlikely 
that the lack of an association in our study is the result of 
confounding. It may simply be due to chance. Death would 
be considered a competing event with HCC, and the MR was 
higher among men than women (adjusted MRR 1.39 [95% 
CI 1.07–1.8]); however, a rate is independent of competing 
events. Similarly, we found no association between diabetes 
Figure 2 Cumulative incidence functions of decompensation comparing SVR, non-SVR, and untreated patients.
Notes: Death, liver transplantation, SVR, treatment initiation, reinfection, coinfection with HIV or HBV, autoimmune hepatitis, and hemochromatosis were considered 
competing events. Non-SVR, treatment with known response that did not result in SVR.
Abbreviations: SVR, sustained virologic response (24 weeks after end of treatment); HBV, hepatitis B virus.
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Figure 3 Cumulative incidence functions of hepatocellular carcinoma comparing patients with SVR, non-SVR, and untreated patients.
Notes: Death, liver transplantation, SVR, treatment initiation, reinfection, coinfection with HIV or HBV, autoimmune hepatitis, and hemochromatosis were considered 
competing events. Non-SVR, treatment with known response that did not result in SVR.
Abbreviations: SVR, sustained virologic response (24 weeks after end of treatment); HBV, hepatitis B virus.
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and HCC, which has been demonstrated consistently,11–13,38 
though mainly after SVR. In our study, diabetes was based 
entirely on the NPR. Misclassification in cases of diabetes 
not registered in the hospital registry may have occurred, 
which would bias the results toward the null. The positive 
predictive value of a diagnosis of diabetes in the NPR has 
been demonstrated to be good.46,47 However, the prevalence 
of diabetes of 12% at baseline in our cohort was at the lower 
end compared to the 12%–24% in other cohorts,11–13,48 which 
could suggest that we have underestimated the true diabetes 
prevalence. Alternatively, since other studies have mainly 
been performed in single or few tertiary centers, it may also 
be that the association between diabetes and HCC demon-
strated by some could be the result of selection bias. Because 
diabetes was introduced as a time-dependent variable in our 
regression analyses, one could argue that this could lead to 
reverse causation of diabetes and HCC, if diabetes was more 
likely to be diagnosed in patients with yet-undiagnosed HCC. 
However, this would lead to a stronger association between 
diabetes and HCC, which was not the case in our study. 
Furthermore, the median time from diabetes to HCC was 
4.6 years and 3.9 years from diabetes to decompensation, 
which makes reverse causation unlikely. Interestingly, in our 
cohort diabetes was associated with HCC in an unadjusted 
analysis and when adjusting for everything but age (data not 
shown). Patients with diabetes were also slightly older than 
patients without diabetes, and the rate of HCC increased 
significantly with age. Therefore, at least in this study, an 
association between diabetes and HCC was confounded by 
age. The HCC IR of 0.85/100 PYs after SVR observed in 
our cohort is consistent with the HCC IRs of 0.55–1.39/100 
PYs described by others after SVR.10,12,38,49,50 The lowest 
HCC IR after SVR was reported in a study by van der Meer 
et al (0.55/100 [95% CI 0.14–0.96] PYs),12 which had a long 
median  follow-up (8.4 years), but included 46% patients 
with advanced fibrosis, slightly younger patients (median 
age 48 years), and only patients with compensated cirrho-
sis. The highest HCC IR estimate reported of 1.39/100 PYs 
was found in a large cohort consisting of 95% males with a 
relatively high prevalence of diabetes and alcohol abuse,38 
all risk factors previously described to be associated with 
HCC.10,12,13,38 Our results on the continuously elevated rate of 
HCC after non-SVR are well within the estimates reported in 
other cohorts of 1.44–5.85/100 PYs.10,12,49–51 We were able to 
confirm the reduced rate of HCC in cirrhotic CHC patients 
associated with SVR reported previously.10,12,49,50 These results 
underscore the benefits associated with a cure for CHC in 
cirrhotic patients. Despite small differences in the definition of 
liver complications applied here and elsewhere, we also found 
a markedly reduced rate of decompensation associated with 
SVR, in line with previous results.10,12,49,50 It is noteworthy that 
the annualized risk of HCC of 1.08% during the first 5 years 
after SVR found in our cohort is below the threshold of cost-
effectiveness of 1.5%/year for HCC surveillance.52,53 However, 
the cutoff was estimated in the 1990s based on patients with 
multiple etiologies and exclusively cirrhosis Child–Pugh A. 
This was during in an era when CHC was difficult to cure, 
with presumably shorter life expectancies. At this point, the 
European Association for the Study of the Liver recommends 
continued HCC surveillance after SVR in cirrhotic patients.16 
Further studies are needed to determine whether surveillance 
for HCC is cost-effective after SVR, and if so, for how long 
after SVR surveillance should be recommended.
The fact that adjusted all-cause and liver-related MRRs 
associated with SVR did not reach statistical significance in 
this study may have been due to underpowering when adjust-
ing for confounding. We are confident that SVR was truly 
associated with reduced mortality in this real-life cohort, as 
Table 4 Adjusted liver-related morbidity and MRRs for patients with SVR vs non-SVR
Adjusted morbidity and mortality rate ratios SVR (95% CI) Non-SVR (95% CI)
All-cause MRR,a SVR vs non-SVR 0.68 (0.43–1.09)
Liver-related MRR,a SVR vs non-SVR 0.6 (0.36–1)
HCC IRR,b SVR vs non-SVR 0.35 (0.21–0.6)
HCC IRR,b diabetes vs non-diabetes 1.14 (0.36–3.61) 1.23 (0.7–2.14)
HCC IRR,b male vs female 1.90 (0.6–5.97) 1.5 (0.89–2.53)
HCC IRR,b alcohol overuse vs no alcohol overuse 1.77 (0.67–4.67) 1.51 (0.97–2.36)
Decompensation IRR,b SVR vs non-SVR 0.31 (0.17–0.57)
Decompensation IRR,b alcohol overuse vs no alcohol overuse 3.38 (1.11–10.28) 1.97 (1.2–3.23)
Decompensation IRR,b diabetes vs no diabetes 1.38 (0.35–5.39) 2.07 (1.18–3.63)
Decompensation IRR,b male vs female 1.88 (0.48–7.31) 0.95 (0.56–1.61)
Notes: aAdjusted for age, sex, alcohol overuse, intravenous drug use, HCC, decompensation, Charlson comorbidity index score, psychiatric disease, and liver transplantation; 
badjusted for sex, age, alcohol overuse, diabetes, HCV genotype (1, 2, 3, 4–6. and multiple genotypes), and SVR as appropriate.
Abbreviations: MRRs, mortality rate ratios; SVR, sustained virologic response (24 weeks after end of treatment); HCC, hepatocellular carcinoma; IRR, incidence rate ratio; 
HCV, hepatitis C virus.
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has been demonstrated previously.23 With highly effective 
DAAs, even patients with advanced liver disease and comor-
bidities can undergo treatment and achieve very high SVR 
rates.16 Therefore, it will be of interest to follow CHC patients 
cured with IFN-free DAA regimens to study the long-term 
effects of eradicating HCV in patients with advanced liver 
disease, comorbidity, and/or substance abuse that would 
have precluded them from IFN and Ribavirin-based therapy.
The unique tradition for nationwide health registries and 
opportunity to cross-link between registries ensured complete 
follow-up in this cohort study of prospectively collected data. 
Unfortunately, only a fraction of the total number of patients 
with CHC in Denmark are aware of their CHC-status and 
attend specialized care,54 which limits the generalizability 
of our morbidity-rate and MR estimates, due to potential 
selection bias. For example, if only the sickest patients attend 
specialized care with symptoms of and complications due to 
CHC, we could have overestimated the rates of liver-related 
morbidity and mortality associated with CHC.
Reporting cancer diagnoses to the Danish cancer registry 
by physicians is mandatory, and since hospitals in Denmark 
are reimbursed based on admissions and procedures regis-
tered in the NPR, the number of HCC cases diagnosed in 
hospitals not registered in the cancer registry, Patobank, or 
NPR is likely to be low. A recent study from Sweden sug-
gests that relying on a single registry could lead to substantial 
underestimation of primary liver cancers, possibly due to 
the noninvasive nature of HCC diagnosis.55 In our study, we 
extracted information from four different registries, which 
confers validity to our results. However, it is possible that we 
underestimated the number of HCC cases due to unrecog-
nized HCC in deceased patients in the absence of diagnostic 
imaging or autopsy. Only two patients were diagnosed with 
HCC exclusively in the registry of causes of death. With 
regard to decompensation, it is likely that the registration of 
this complication is less rigorous than HCC, since we had 
to rely on only two registries, and thus it is possible that we 
underestimated the occurrence of decompensation.
Other limitations include the fact that we did not have 
information about smoking status, valid HCV RNA con-
centrations, body-mass index, nonalcoholic fatty-liver dis-
ease, nonalcoholic steatohepatitis, CHC disease duration, 
Child–Pugh or MELD (model for end-stage liver disease) 
score, systematic information about cirrhosis regression, 
quantification and duration of alcohol intake, or information 
about current alcohol overuse or IDU. These are all important 
potential confounding factors.
In conclusion, we found high rates of liver-related 
morbidity and mortality among patients with CHC and cir-
rhosis, in particular among untreated patients. Genotype 3 
and alcohol overuse were associated with increased rates of 
HCC, and diabetes and alcohol overuse increased the rate 
of decompensation. Successful eradication of HCV was 
associated with substantially reduced rates of liver-related 
mortality, HCC, and liver decompensation when adjusting 
for confounding. There continues to be an urgent need to cure 
patients with CHC and cirrhosis before the development of 
complications, particularly in those with genotype 3. Special 
attention should be given to patients with a history of alcohol 
overuse in whom an elevated rate of HCC and decompensa-
tion remain after SVR.
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Supplementary materials
Data sources
Danish civil registration system, Danish Database for Hepa-
titis B and C (DANHEP), Danish national patient registry 
(NPR), national Danish pathology database (Patobank), and 
Danish cancer registry provided in supplementary material 
published previously.1
The Danish register of causes of death (DAR) is a nation-
wide registry that contains information on nearly every death 
in Denmark since 1943. On each death certificate, a physician 
has registered one or more diagnoses considered to be the 
cause(s) of death, and coded with appropriate ICD-10 codes 
during this study period.2
Definition of covariates
Lists of ICD-8, ICD-10, and SNOMED codes used in the 
definition of inclusion and exclusion criteria, covariates, and 
causes of death are supplied in Tables S1–S5.
Figure S1 Inclusion and exclusion of patients with CHC and cirrhosis.
Abbreviations: PIN, personal identification number; HCV, hepatitis C virus; CHC, chronic hepatitis C; CHB, chronic hepatitis B; TE, transient elastography; SVR, sustained 
virologic response; HCC, hepatocellular carcinoma.
5,779 patients with valid
PIN and + HCV-RNA
4,080 patients with ≥1
fibrosis evaluation
1,306 patients with
cirrhosis
1,038 eligible patients with
CHC and cirrhosis
1,038 at risk of mortality
360 died
1 lost to follow-up
677 censored alive
153 decompensated 115 HCC
811 patients at risk
of decompensation
519 patients treated
501 untreated patients
10 patients had
unknown response
303 achieved non-
SVR at least once
233 achieved SVR
989 patients at risk
of HCC
268 excluded:
Death within 6 months87
76 Baseline after 31 Dec 2013
50 HIV
35 Chronic hepatitis B (CHB)
5 HIV and CHB
5 Autoimmune hepatitis
4 Hemochromatosis
4 Biopsy <F4 and TE> 17 kPa
2 Acute hepatitis C
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Table S1 Codes for assorted conditions
Cirrhosis
National Danish pathology database 
(Patobank)
SNOMED: M49500, M49501, M49503, M49504, M49506, M49510, M49514, M49516, M49520, 
M49524, M49526, M49527, M49528, M49530, Æyyya4, ÆYYYA4
National patient registry (NPR) ICD-10: K74.6
Esophageal varices: ICD-8, 456.09, 456.00, 456.01; ICD-10, I85.X, I86.4
Esophageal variceal hemorrhage: ICD-8, 456.01; ICD-10, I85.0
Ascites: ICD-8, 785.39; ICD-10, R18, R18.9, KTJA10A, KTJA10B
Hepatic encephalopathy/liver failure: ICD-8, 57300; ICD-10, K72, B19.0, G92.9, G93.4
Spontaneous bacterial peritonitis: ICD-10, K65.8I
Danish Database for Hepatitis B and C 
(DANHEP)
Esophageal varices, ascites, hepatic encephalopathy
Registry of causes of death (DAR) Esophageal varices: ICD-10, I85.X, I86.4
Esophageal variceal hemorrhage: ICD-10, I85.X, I86.4
Ascites: ICD-10, R18, R18.9
Hepatic encephalopathy or liver failure: ICD-10, K72, B19.0, G92.9, G93.4
Spontaneous bacterial peritonitis: ICD-10, K65.8I
Chronic hepatitis B
DANHEP A positive HBsAg
HIV/AIDS
DANHEP A positive HIV-antibody/antigen test
NPR ICD-8, 07.983; ICD-10, B20.0–24.9
Autoimmune hepatitis
NPR ICD-10, K75.4, K73.2
Patobank SNOMED, S63580
Hemochromatosis
NPR ICD-8, 273.29; ICD-10, E83.1A
Patobank SNOMED, S11920
Wilson’s disease
NPR ICD-8, 273.39; ICD-10, E83.0B
Patobank SNOMED, S87250
Hepatocellular carcinoma
Danish cancer registry (CAR) ICD-10, C22.0, C22.9
NPR ICD-10, C22.0, C22.9
Patobank SNOMED, M81703, M81704, M81706, M81707, M81709
DAR ICD-10, C22.0, C22.9
Liver transplantation
NPR ICD-10, Z94.4, KJJC, KJJC00, KJJC10, KJJC20, KJJC96, DZ944, DT864, DT864A, DT864B
History of alcohol abuse
DANHEP Self-reported alcohol consumption of more than 3 units of alcohol per day for men and 2 units per day 
for women
NPR ICD-8, 291.00–291.99, 571.09, 571.10, 303.00–303.89, 303.91–303.99; ICD-10, K 70.0–70.9, F10.2–
F10.9, G31.2
Patobank SNOMED, S63590, M49660
History of intravenous drug abuse
DANHEP Self-reported intravenous drug use or route of transmission of HCV as intravenous drug use
NPR ICD-8, 304.09–304.99; ICD-10, F11.0–F19.9, T40.0–T40.9
Psychiatric disease
NPR ICD-8, 295.00–302.99, 305.00–315.99; ICD-10, F20.0–FF99.9
Decompensated liver cirrhosis
NPR Esophageal variceal hemorrhage: ICD-8, 456.01, ICD-10, I85.0
Ascites: ICD-8, 785.39; ICD-10, R18, R18.9, KTJA10A, KTJA10B
Hepatic encephalopathy or liver failure: ICD-8, 57300; ICD-10, K72, B19.0, G92.9, G93.4
Spontaneous bacterial peritonitis: ICD-10, K65.8I
DANHEP Esophageal varices, ascites, hepatic encephalopathy
DAR Esophageal variceal hemorrhage: ICD-10, I85.X, I86.4
Ascites: ICD-10, R18, R18.9
Hepatic encephalopathy or liver failure: ICD-10, K72, B19.0, G92.9, G93.4
Spontaneous bacterial peritonitis: ICD-10, K65.8I
Abbreviations: SNOMED, systematized nomenclature of medicine; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; ICD-10, 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems.
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Table S2 ICD codes used in definition of Charlson comorbidity index score
Comorbid conditionsa ICD-8 ICD-10 Score
Myocardial infarction 410 I21.x, I22.x, I25.2 1
Congestive heart failure 427.09, 427.10, 427.11,427.19, 428.99, 
782.49
I09.9, I11.0, I13.0, I13.2, I25.5, I42.0, I42.5–I42.9, 
I43.x, I50.x, P29.0
1
Peripheral vascular disease 440–445 I70.x, I71.x, I73.1, I73.8, I73.9, I77.1, I79.0, I79.2, 
K55.1, K55.8, K55.9, Z95.8, Z95.9
1
Cerebrovascular disease 430–438 G45.x, G46.x, H34.0, I60.x–I69.x 1
Dementia 290.09–290.19, 293.09 F00.x–F03.x, F05.1, G30.x, G31.1 1
Chronic pulmonary disease 490–493, 515–518 I27.8, I27.9, J40.x–J47.x, J60.x–J67.x, J68.4, J70.1, 
J70.3
1
Rheumatic disease 712, 716, 734, 446, 139.99 M05.x, M06.x, M31.5, M32.x–M34.x, M35.1, M35.3, 
M36.0
1
Peptic ulcer disease 530.91, 530.98,531–534 K25.x–K28.x 1
Diabetes without chronic 
complication
249.00, 249.06, 249.07, 249.09, 250.00, 
250.06, 250.07, 250.09
E10.0, E10.1, E10.6, E10.8, E10.9, E11.0, E11.1, 
E11.6, E11.8, E11.9, E12.0, E12.1, E12.6, E12.8, 
E12.9, E13.0, E13.1, E13.6, E13.8, E13.9, E14.0, 
E14.1, E14.6, E14.8, E14.9
1
Diabetes with chronic complication 249.01–249.05, 249.08, 250.01–250.05, 
250.08
E10.2–E10.5, E10.7, E11.2–E11.5, E11.7, E12.2–
E12.5, E12.7, E13.2–E13.5, E13.7, E14.2–E14.5, E14.7
2
Hemiplegia or paraplegia 344 G04.1, G11.4, G80.1, G80.2, G81.x, G82.x, G83.0–
G83.4, G83.9
2
Renal disease 403, 404, 580–584, 590.09, 593.19, 
753.10–753.19, 792
I12.0, I13.1, N03.2–N03.7, N05.2–N05.7, N18.x, 
N19.x, N25.0, Z49.0–Z49.2, Z94.0, Z99.2
2
Any malignancy, including lymphoma 
and leukemia, except malignant 
neoplasm of skin
140–15.429, 15.519–194, 200–203, 204–207 C00.x–C21.x, C23.x–C26.x, C30.x–C34.x, C37.x–
C41.x, C43.x, C45.x–C58.x, C60.x–C76.x, C81.x–
C85.x, C88.x, C90.x–C97.x
2
Metastatic solid tumor 195–199 C77.x–C80.x 6
Notes: aAIDS-related diagnoses were not relevant, since patients and controls with HIV/AIDS were excluded. Liver disease-related diagnoses and hepatocellular carcinoma 
were considered to be part of the causal path between cirrhosis and death, and thus were not included. All ICD-10 codes are according to Quan et al.3
Abbreviation: ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems.
Table S3 Causes of death
Cause of death ICD-10 codes registered in registry of causes of death
Liver-related Viral hepatitis (B15–B19, B94.2)
Primary liver cancer (C22.x)
Alcoholic liver disease (K70.x)
Other liver diseases (K71–K78)
Liver-unrelated Chronic lung diseases (J40–J47)
Ischemic heart diseases (I20–I25)
Cerebrovascular diseases (I60–I69)
Diabetes mellitus (E10–E14)
Lung cancer (C34.x)
Pancreatic cancer (C25.x)
Non-Hodgkin’s lymphoma (C83.x)
Kidney cancer (C64.x)
Colorectal cancer (C18–C20)
Other cancers (C and D, except for C18–CC20, C22, C25, C34, C64, C83)
Alcohol abuse (F10.x)
Opioid abuse (F11.x)
Other substance abuse (F12–19)
Other natural causes (all other natural deaths) Accidents (X00–X39, X50–X59, V01–V99, W00–W99)
Suicide (X60–X84)
Accidental poisoning (X40–X49)
Assault (X85–X99, Y00–Y09)
Injuries (S00–S99, T00–T35, T90–T98)
Poisoning (T36–T50)
Other unnatural causes (T51–T89, Y10–Y98)
Abbreviation: ICD-10, 10th revision of the International Statistical Classification of Diseases and Related Health Problems.
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Table S4 Characteristics of patients with SVR and non-SVR at their first EOT24 date or baseline, whichever occurred last
Patient characteristics SVR Non-SVR P-value
n 233 276
Age (median years, range) 51.3 (29–75) 53.9 (28–80) P=0.0001
Sex, n (%)
Male 148 (63.5) 189 (68.5) P=0.2
CCI score, median (range)a
0, n (%)
1–2, n (%)
3–5, n (%)
≥6, n (%)
0 (0–6)
148 (63.5)
74 (31.8)
10 (4.3)
1 (0.4)
0 (0–6)
161 (58.3)
99 (35.9)
15 (5.4)
1 (0.4)
P=0.2
Psychiatric disease, n (%) 43 (18.5) 47 (17) P=0.67
Diabetes mellitus, n (%) 29 (12.5) 40 (14.5) P=0.5
Continent of birth, n (%)
Europeb
Africa
Asia
Other
Unknown
176 (75.5)
6 (2.6)
41 (17.6)
4 (1.7)
6 (2.6)
227 (82.3)
17 (6.2)
28 (10.1)
2 (0.7)
2 (0.7)
P=0.02
Route of transmission, n (%)
IDU
Tattoo/piercing
Vertical
Sexual transmission
Blood/blood-product exposure
Needle injury
Multiple
Other reason
Unknown
109 (46.8)
8 (3.4)
0
4 (1.7)
14 (6)
1 (0.4)
2 (0.9)
5 (2.2)
90 (38.6)
138 (50.0)
8 (2.9)
2 (0.7)
2 (0.7)
22 (8)
1 (0.4)
3 (1.1)
2 (0.7)
98 (35.5)
P=0.6
Diagnostic basis for cirrhosis, n (%)
Liver biopsy
Clinical cirrhosis
Transient elastography
164 (70.4)
35 (15.0)
34 (14.6)
185 (67)
59 (21.4)
32 (11.6)
P=0.15
Decompensated cirrhosis, n (%) 19 (8.2) 33 (12) P=0.16
Hepatocellular carcinoma, n (%) 5 (2.2) 14 (5.1) P=0.08
HCV genotypes, n (%)
1c
2
3
4-6
Unknown
77 (33.1)
20 (8.6)
107 (45.6)
5 (2.2)
24 (10.3)
144 (52.2)
9 (3.3)
99 (35.9)
11 (4)
13 (4.7)
P<0.0002
ALT, IU/L, median, IQR (n=502) 43 (27–105) 86 (52–139) P<0.0001
Alcohol overuse ever,d n (%) 94 (40.3) 135 (48.9) P=0.05
IDU ever,d n (%) 113 (48.5) 149 (54) P=0.22
Notes: aAll patients with no known CCI score at the first EOT24-date or baseline, whichever occurred last, were set to have a CCI score of 0; bGreenland is part of 
Denmark; cthree patients had genotypes 1 and 2 and nine patients had genotypes 1 and 3; dnumber overall and percentages of patients with IDU/alcohol overuse before end 
of follow-up.
Abbreviations: SVR, sustained virologic response; EOT24, 24 weeks after end of treatment; HCV, hepatitis C virus; IDU, intravenous drug use; CCI, Charlson comorbidity 
index; IQR, interquartile range.
Table S5 Cumulative incidences for liver-related morbidity among all patients at risk after SVR, after non-SVR, and among untreated 
patients, with death and LTx as competing risks
Morbidity All patients, 
% (95% CI)
After SVR,  
% (95% CI)
After non-SVR,  
% (95% CI)
Untreated time,  
% (95% CI)
HCC, 1-year 1.35 (0.62–2.08) 0.48 (0–1.41) 2.55 (0.68–4.42) 1.28 (0.33–2.23)
HCC, 5-year 9.14 (7.08–11.2) 5.38 (1.87–8.88) 13.25 (8.65–17.85) 9.79 (6.45–13.12)
HCC, 10-year 18.3 (14.88–21.71) 6.38 (2.39–10.37) 26.16 (18.7–33.62) 18.99 (13.19–24.8)
Decompensation, 1-year 5.2 (3.65–6.76) 1.50 (0–3.19) 3.91 (1.53–6.29) 7.57 (4.95–10.19)
Decompensation, 5-year 15.79 (13–18.6) 5.58 (1.95–9.21) 19.25 (13.67–24.84) 20.86 (15.65–26.07)
Decompensation, 10-year 28.23 (23.97–32.48) 6.64 (2.5–10.79) 34.69 (26.5–42.89) 36.12 (27.9–44.34)
Note: Death and LTx were treated as competing risks.
Abbreviations: SVR, sustained virologic response (24 weeks after end of treatment); LTx, liver transplantation; HCC, hepatocellular carcinoma.
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